Search clinical trials for: In Vitro Kinase Inhibitor Assay

Total 9051 results

AbbVie

Recruiting

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting (UpSPINE)

Axial Spondylarthritis (r-axSpA)

Germany
Pfizer

Completed

Safety And Efficacy Of Bosutinib (BLF)

Chronic Myelogenous Leukemia

Japan
University of Birmingham
Pfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer...

Active, not recruiting

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Non-Small Cell Lung Cancer

United Kingdom
Hospices Civils de Lyon

Unknown

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (CHLOROTRAMMEL)

Metastatic NRAS Melanoma

France
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

Prurigo Nodularis | Itch

China
Novartis Pharmaceuticals

Recruiting

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)

Recruiting

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Chronic GVHD

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for ABL001, Asciminib

Chronic Myeloid Leukemia in Chronic Phase
Pfizer

Completed

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Metastatic Non Small Cell Lung Cancer

India
Novartis Pharmaceuticals

Active, not recruiting

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Gastrointestinal Stromal Tumors

Germany, Italy, France, Finland
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

Systemic Lupus Erythematosus | Cutaneous Lupus

United States
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
Pfizer

Completed

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Carcinoma, Renal Cell

United States
Arvinas Estrogen Receptor, Inc.
Pfizer

Active, not recruiting

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E)

Breast Cancer

United States, Spain
Mayo Clinic

Not yet recruiting

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Chronic Graft Versus Host Disease | Hematopoietic and Lymphatic System Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
Shanghai Zhongshan Hospital

Not yet recruiting

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

Glucocorticoid Resistant ICIs-related Myocarditis
Novartis Pharmaceuticals

Recruiting

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Pfizer

Completed

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Neoplasm Metastasis | Carcinoma, Non-Small Cell

United States, France, Spain
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca

Completed

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Pneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar Feature

France
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Hospital Clinic of Barcelona
Centers for Disease Control and Prevention; Ifakara Health Institute; Kenya Medical... and other collaborators

Completed

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy (MiPPAD)

HIV Infections | Pregnancy | Malaria

Benin, Gabon, Kenya, Mozambique, Tanzania
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Completed

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Cancer | Head and Neck Cancer | Thoracic Neoplasms | Nervous System Neoplasms | Pelvic Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...

United States
Brian Druker
AbbVie; Oregon Health and Science University; Incyte Corporation

Active, not recruiting

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Myelofibrosis

United States
Ruijin Hospital

Active, not recruiting

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)

Pulmonary Metastases | Osteosarcoma | Apatinib

China
University Hospital, Caen

Not yet recruiting

Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Atrial Fibrillation | Hematological Malignancy

France
Khashayar Esfahani

Recruiting

Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study

Immune-Mediated Colitis

Canada
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Korea, Republic of, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more
Hoffmann-La Roche

Active, not recruiting

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (ReAlec)

NSCLC

Belgium, Australia, China, Croatia, Finland, Turkey, Italy, Israel, Serbia, Austria, Romania, Peru, Lithuania, Colombia, Portugal, Czechia, Cuba, Russian Federation, Bulgaria, Vietnam, Uruguay, United Arab Emirates, Argentina, Chile, Pa...
Beijing Friendship Hospital

Completed

Zanubrutinib for HLH

HLH

China
Astellas Pharma Global Development, Inc.
National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant...

Completed

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Japan, Korea, Republic of, Taiwan, Spain, Italy, United Kingdom, Australia, Belgium, Canada, Denmark, France, Germany, Greece, New Zealand, Poland
Institute of Dermatology, Thailand

Enrolling by invitation

Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study (Tofacitinib)

Frontal Fibrosing Alopecia | Lichen Planopilaris

Thailand
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (HS:Hansoh;)

Advanced Cancer

China
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies (PI3K)

Lymphoma, B-Cell | T-Cell Lymphoma

France, Italy
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
Kazia Therapeutics Limited
Quotient Sciences

Completed

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Terminated

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Cancer
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
Chen Miao

Recruiting

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Warm Autoimmune Hemolytic Anemia

China
AbbVie

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus

United States, Japan, Puerto Rico, Switzerland, Israel, Korea, Republic of, Hungary, New Zealand, Bulgaria, Latvia, Taiwan, Slovakia, Croatia, South Africa, Australia, Poland, Portugal, Spain, Estonia, France, Lithuania, Brazil, Ger... and more

Search clinical trials for: In Vitro Kinase Inhibitor Assay

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations